HomeDealsNegotiationsPolicyPipelineMoneyPeopleDataThe WeekPharmTech 100Deal TrackerResearch
Deals

Amneal to buy a biosimilar company; Samsung Bio workers protest

Plus, news about Avonik, a supply chain transparency bill and Nucleus RadioPharma: 💰 Amneal Pharmaceuticals to acquire biosimilar maker for $375M upfront: The generics and specialty drugmaker is set to buy ...

By Endpoints News · Apr 23, 2026 · via Endpoints News
Amneal to buy a biosimilar company; Samsung Bio workers protest

Image: Endpoints News

Tags
dealsformat:headlineheadlineEndpoints News
The Insider - Weekly pharma intelligence
Deals, negotiations, and policy analysis. Delivered when it matters.
No sponsored content. No noise. Unsubscribe anytime.
More from Deals
All Deals →
After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?
DealsFierceBiotech ↗
After Lilly’s $7B Kelonia deal, are there any in vivo CAR-T biotechs left to buy?
Despite the recent “feeding frenzy,” Pitchbook’s Ben Zercher told Fierce he expects in vivo CAR-T dealmaking t…
Apr 25, 2026
UCB Buys Neurona for $650M to Deepen Epilepsy Bet
DealsBriefing
UCB Buys Neurona for $650M to Deepen Epilepsy Bet
UCB’s $650 million deal for Neurona Therapeutics signals a move to blend neurology heritage with next‑gen cell…
Apr 22, 2026
Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B
DealsFierceBiotech ↗
Lilly picks up another in vivo CAR-T company with Kelonia buyout worth up to $7B
Eli Lilly is picking up its second in vivo CAR-T company of the year, paying $3.25 billion in upfront cash for…
Apr 21, 2026